Douglas Spitz
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive and chemo-resistant sarcomas with poor survival rates. Loss of CDKN2A or P53 following NF1 disruption is a key event in MPNST development. Here, we used CRISPR-Cas9 somatic tumorigenesis in mice to identify transcriptomic and metabolomic features distinguishing CDKN2A - versus P53 -deleted MPNSTs. Convergent, multiomic analyses revealed that CDKN2A -deleted MPNSTs are especially dependent on the pentose phosphate pathway (PPP) and NADPH metabolism for growth and viability. Disruption of glucose-6-phosphate dehydrogenase (G6PD), the PPP rate-limiting enzyme, slowed CDKN2A -deleted MPNST growth and sensitized MPNSTs to standard-of-care chemotherapy. Knockdown of the redox-regulated transcription factor NRF2 slowed MPNST growth and decreased G6PD transcription. Analysis of patient MPNSTs identified a NRF2 gene signature correlating with tumor transformation. Furthermore, G6PD and NRF2 expression in PanCancer TCGA samples correlates with patient survival. This work identifies NRF2-PPP dependency as a targetable vulnerability in these difficult-to-treat MPNSTs, particularly in the NF1/CDKN2A -deleted majority.
Year:
2025
Introduction Small cell lung cancer (SCLC) has a 7% 5-year overall survival. C-X-C chemokine receptor 4 (CXCR4), an attractive target for theranostic agents, is highly expressed in SCLCs, and can be targeted with pentixather using the theranostic pair 212 Pb/ 203 Pb. The hypothesis that [ 212 Pb/ 203 Pb]-pentixather can be used safely and effectively for imaging and therapy in SCLC in xenograft models was tested. Results SPECT/CT imaging and biodistribution studies of tumor bearing mice injected with [ 203 Pb]-pentixather demonstrated CXCR4-dependent uptake in tumors and accumulation of radioligand in kidneys and livers. Dosimetry calculations estimated [ 212 Pb]-pentixather uptake in tumor and normal tissue. [ 212 Pb]-pentixather treatment (37-111 kBq/g) of SCLC xenografts (DMS273 and H69AR) significantly prolonged survival and delayed tumor growth. When NSG mice grafted with human hCD34+ bone marrow were treated with [ 212 Pb]-pentixather (37-111 kBq/g), significant cytopenias were observed in peripheral blood complete blood counts (CBCs) at 13-18 days post treatment which resolved by day 28-31. Flow cytometry of bone marrow hematopeotic stem cells in these animals at day 28-31 demonstrated a significantly reduced frequency of the human hematopoietic marker CD45 (hCD45+) and reconstitution of the bone marrow with murine CD45+ (mCD45+) lineages. Conclusions [ 203 Pb]-pentixather can be used to image CXCR4 expressing SCLC xenografts and treatment with alpha emitter [ 212 Pb]-pentixather significantly prolongs SCLC xenograft median overall survival. Significantly greater mCD45+ bone marrow repopulation was detected in NSG mice engrafted with human bone marrow 28-31 days following [ 212 Pb]-pentixather treatment, relative to hCD45+ bone marrow.
Year:
2024
Purpose: Pharmacologic ascorbate (P-AscH − ) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH − with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T 2 * mapping to predict GBM response to P-AscH − in humans. Patients and Methods: The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T 2 *-based MRI to assess its utility as an Fe-dependent biomarker. Results: Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T 2 * relaxation 2 *-high subjects (11.2 months vs. 5.7 months, P in vitro and in vivo model systems. Conclusions: P-AscH − combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T 2 *-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes. See related commentary by Nabavizadeh and Bagley, p. 255
Year:
2024
Purpose: Pharmacologic ascorbate (P-AscH − ) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH − with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T 2 * mapping to predict GBM response to P-AscH − in humans. Patients and Methods: The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T 2 *-based MRI to assess its utility as an Fe-dependent biomarker. Results: Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T 2 * relaxation 2 *-high subjects (11.2 months vs. 5.7 months, P in vitro and in vivo model systems. Conclusions: P-AscH − combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T 2 *-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes. See related commentary by Nabavizadeh and Bagley, p. 255
Year:
2024
Collaborators (18)
John Buatti
Professor
The University of Iowa
Kranti Mapuskar
Associate Research Scientist
The University of Iowa
Stephen Graves
Associate Professor
The University of Iowa
Adam Rauckhorst
Assistant Professor of Cellular and Molecular Medicine
Florida International University
Nicholas Borcherding
Assistant Professor
University of Washington Medical Center
Joseph J. Cullen
-
Jeremy D. W. Greenlee
-
Rebecca Dodd
Assistant Professor
The University of Iowa
Brian Smith
Professor
Iowa State University
Bryan Allen
Professor/Chair and DEO
University of Iowa Healthcare
Varun Monga
Clinical Associate Professor
University of California San Francisco Medical Center
Ryan Flynn
Medical Physics Division Director
The University of Iowa
Vincent Magnotta
Professor
Iowa State University
Garry Buettner
Professor
Iowa State University
Muhammad Furqan
Professor
University of Oklahoma Health Sciences Center
Jon Houtman
Professor
Iowa State University
Joel J. St‐Aubin
-
Karra A Jones
Associate Professor
Duke University
Make your next move.
Prepare your application
Review drafts before you send them.